Exagen Inc. (XGN)

NGM – Real Time Price. Currency in USD

4.58

-0.06 (-1.29%)

At close: Jun 26, 2026, 4:00 PM EDT

4.64

+0.06 (1.31%)

After-hours: Jun 26, 2026, 5:05 PM EDT

01.06.2026

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared with conventional serologic tests alone.

28.05.2026

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

12.05.2026

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

11.05.2026

Exagen Q1 Earnings Call Highlights

Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.

11.05.2026

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.2 per share a year ago.

11.05.2026

Exagen Inc. Reports First Quarter 2026 Results

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

28.04.2026

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago.

Videos

No Data

There is no data to display

Press releases

01.06.2026

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

11.05.2026

Exagen Inc. Reports First Quarter 2026 Results

10.03.2026

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.

11.01.2026

Exagen Inc. Announces Select Preliminary 2025 Financial Results

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.

Exagen Inc. (XGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exagen Inc. (XGN)

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen Q1 Earnings Call Highlights

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. Reports First Quarter 2026 Results

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Videos

No Data

Press releases

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Exagen Inc. Reports First Quarter 2026 Results

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen Q1 Earnings Call Highlights

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. Reports First Quarter 2026 Results

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Videos

No Data

Press releases

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Exagen Inc. Reports First Quarter 2026 Results

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Search stocks

Exagen Inc. (XGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exagen Inc. (XGN)

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen Q1 Earnings Call Highlights

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. Reports First Quarter 2026 Results

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Videos

No Data

Press releases

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Exagen Inc. Reports First Quarter 2026 Results

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen Q1 Earnings Call Highlights

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen Inc. Reports First Quarter 2026 Results

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Videos

No Data

Press releases

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Exagen Inc. Reports First Quarter 2026 Results

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen Inc. Announces Select Preliminary 2025 Financial Results